The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children—A pivotal phase III trial
Allergy · 2025
DOI: 10.1111/all.16363 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Allergy, 2025. Verfasst von Monika Gappa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Paediatric and Adolescent Medicine, Evangelic Hospital Düsseldorf, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Allergens, Rhinitis, Allergic, Seasonal, Trees. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The study and manuscript writing were funded by ALK-Abelló, Hørsholm, Denmark.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Allergic rhinitis and/or conjunctivitis (AR/C) induced by tree pollen is common and negatively impacts quality of life in children and adolescents. This phase III trial investigated the efficacy and safety of the SQ tree SLIT‐tablet in a paediatric population (5–17 years) with moderate‐to‐severe AR/C induced by pollen from birch and trees in the birch homologous group.
Methods
Nine hundred and fifty‐two subjects were randomized (1:1) to daily treatment with SQ tree SLIT‐tablet or placebo for up to 52 weeks and had free access to AR/C symptom‐relieving medications. The primary endpoint was the average total combined score (TCS); sum of average daily symptom score (DSS) and average daily medication score (DMS) during the birch pollen season (BPS). Key secondary endpoints included average DSS and DMS during BPS and average TCS, DSS and DMS during tree pollen season (TPS).
Results
SQ tree SLIT‐tablet demonstrated a statistically significant and clinically relevant treatment effect compared with placebo for the TCS during BPS with an absolute treatment difference of 1.29 (95% CI: 0.58, 2.00; p = .0004) and a relative reduction of 21.9% (95% CI: 10.6, 31.9). Results were substantiated by reductions in both DSS and DMS versus placebo during the BPS and in DSS, DMS and TCS during the TPS. Treatment was generally well tolerated. Most treatment‐related adverse events were mild or moderate local administration site reactions.
Conclusion
This is the first paediatric trial to provide robust evidence of efficacy and safety of the SQ tree SLIT‐tablet in tree pollen‐induced AR/C in a paediatric population (5–17 years).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Paediatric and Adolescent Medicine, Evangelic Hospital Düsseldorf, Düsseldorf, Germany.
- Clinique spécialisée en allergie de la capitale, Québec City, Québec, Canada.
- Allergiezentrum Wien West, Vienna, Austria.
- Department of Pediatrics, Jagiellonian University Medical College, Kraków, Poland.
- ALK-Abelló, Hørsholm, Denmark.
- Pediatric clinic, University hospital in Martin and Jessenius medical faculty in Martin, Commenius University, Bratislava, Slovakia.
ORCID-Profile: Monika Gappa, Fritz Horak, Ewa Cichocka-Jarosz, Oliver Pfaar
Förderung
- The study and manuscript writing were funded by ALK-Abelló, Hørsholm, Denmark
Zitieren
APA
Gappa, M., Gagnon, R., Horak, F., Cichocka-Jarosz, E., Dalgaard, T., Hargreaves, K., Mikler, J., Emeryk, A., Hansen, K. S., & Pfaar, O. (2025). The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children—A pivotal phase III trial. Allergy. https://doi.org/10.1111/all.16363
Vancouver
Gappa M, Gagnon R, Horak F, Cichocka-Jarosz E, Dalgaard T, Hargreaves K, et al. The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children—A pivotal phase III trial. Allergy. 2025. doi:10.1111/all.16363
BibTeX
@article{Gappa2025,
author = {Gappa, Monika and Gagnon, Rémi and Horak, Fritz and Cichocka-Jarosz, Ewa and Dalgaard, Terrie and Hargreaves, Kate and Mikler, Jan and Emeryk, Andrzej and Hansen, Kirsten Skamstrup and Pfaar, Oliver},
title = {The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children—A pivotal phase III trial},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16363}
}
EUVIMED